LungCancerRx 🫁💊

Episode 2 is OUT!!! 🎙️ @jillfeldman4 @EGFRResisters discusses how patients with EGFR+ lung cancer can make empowered choices in clinic! @lungoncdoc @FawziAbuRous @ADesaiMD oncologynewscentral.com/video/lung-can…

Missing our third musketeer here at #BTGLung2025! @ADesaiMD @lungoncdoc @FawziAbuRous

Magnitude of OS benefit for FLAURA2 will be relevant here. Since crossover was not mandated per study design, the next question should be what did the control arm receive and when? IMO - the central clinical, real world, question that FLAURA2 is trying to answer is whether…

📢 The updated @ASCO Living Guidelines for NSCLC without a driver alteration are now published in @JCO_ASCO! We reviewed key new data including HARMONI-2, NIPPON, and more. @BalazsHalmosMD @dwightowenmd ascopubs.org/doi/10.1200/JC…

‼️Press release: #FLAURA2 shows osimertinib + chemo improves OS in EGFR+ lung cancer — “statistically significant & clinically meaningful.” Combos may be in, but informed & shared decision-making stays key. Excited to review full data! @OncoAlert

New 5-year data from #IMpower010 @JCO_ASCO ☑️PD-L1 ≥50%: Strongest benefit – recommend adjuvant atezolizumab. ☑️PD-L1 ≥1%: Meaningful DFS benefit, trending OS benefit – atezo is supported. ☑️PD-L1 negative/unknown: No proven benefit – not routinely recommended.…

#lungcancer #LCSM

This slide is SO important. As someone who treats patients with young-onset lung cancer, I see it every day: long-term toxicities matter just as much as the short-term ones. @YoungLungCancer #NOSCM25

Thank you @jillfeldman4 @EGFRResisters for joining us!! If you haven’t listened to EPISODE 2 of @LungCancerRx yet, do so ASAP! 🎙️ @lungoncdoc @FawziAbuRous @ADesaiMD

🎙️ New #LungCancerRx episode is live! 20 mins on the most important conversations to have when EGFR+ NSCLC patients are choosing 1st-line therapy w/ @lungoncdoc @FawziAbuRous @ADesaiMD @jillfeldman4 @EGFRResisters 🎧 bit.ly/4lz1zlW #NSCLC #MedEd #OncTwitter

🎙️ Episode 2 of the #LungCancerRx podcast is out now! We dive into shared decision-making and how to empower patients in navigating treatment choices. Featuring @jillfeldman4, @lungoncdoc, @ADesaiMD In collaboration with @EGFRResisters & @OncNewsCentral Listen + subscribe!…

📚 Hem/Onc boards are around the corner! Check out my interview on ASCO Connection where I share tips, strategies, and insights from my own board prep journey. Hope it helps those getting ready! connection.asco.org/do/prepared-me… #MedTwitter #OncTwitter #HemOnc #BoardExams #Fellowship…

It's that time! If you are a fellow, Jr faculty, or post doc doing research in #EGFR #lungcancer, submit your abstract for a chance to join us in Chicago, Nov 6-8, at the @EGFRResisters Research Summit. Great opportunity to network with thought leaders in #lungcancer, other…

🧬 New narrative review on 1L treatment for advanced NSCLC: onlinelibrary.wiley.com/doi/10.1111/17… ✅ IO ± chemo/dual IO improves outcomes ❌ But 5y OS still ~25–30% 📉 Plateau demands innovation: biomarkers, new combos, better selection Time to break the checkpoint gridlock. The horizon…

Thanks to @StephenVLiu & @NarjustFlorezMD for the opportunity to showcase the upcoming @IASLC #WCLC25 conference in Barcelona Join us Sept 6-9, for the very best in thoracic oncology @NReguart @IsaOpitz @UmbertoMalapel1 #LCSM

We don’t talk enough about what it’s like to lose the friends you met through cancer. It’s a grief layered with love, trauma, and deep understanding. Leah & Cori, two patients with lung cancer, open up 🎥👇 #CancerGrief #LungCancerAwareness

SCLC transformation from EGFR+ NSCLC, outcomes & tx? @ESMO_Open: - 25pts: CT (n=12), CT+EGFR-TKI (n=5), CT+ICI (n=6), CT+ICI+TKI (n=1) - mPFS 2m; mOS 9m, similar across tx - mOS if transf >12m v <12m (31m vs 8m, p<0.001) @ChiaraCATANIA4 @OncoAlert #LCSM esmoopen.com/article/S2059-…

⭐️A fantastic, balanced, and comprehensive editorial from @RobertoFerrara_ & colleagues - they do an elegant job dissecting many of my concerns with the state of IO clinical trial development. KEY POINTS: 1️⃣ Not all ICIs are equivalent & bind to varied epitopes. While single…

We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing! oncodaily.com/blog/aakash-de…

Have you caught up on Episode 1 of @LungCancerRx yet? Your refill is almost due… because Episode 2 drops NEXT WEEK! 🎧💥 @OncNewsCentral @lungoncdoc @FawziAbuRous @ADesaiMD @jillfeldman4